Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Response Biomedical (V.RBM) -- Ignore unavailable to you. Want to Upgrade?

To: Starowl who wrote (383)	3/3/2001 3:50:37 AM
From: Dick Martin	Read Replies (1) \| Respond to of 655

Shareholder letter of Mar 2 Dear Shareholder, On January 11, 2001, I committed to achieving a series of milestones key to the commercialization of the RAMP System. I am pleased to report that the first milestone was achieved on schedule. a Myoglobin Test and RAMP Reader in Beta Trials January 2001 We conducted this preclinical study at two local institutions: St. Paul's Hospital, which has one of Vancouver's busiest emergency departments, and CEQAL, Inc., Canada's leading reference laboratory. The study was successful and the feedback we received from participants has helped us make final preparations for our FDA clinical trial, scheduled to begin this month. Most importantly, the results of the study have encouraged me that we are on target to meet the remaining milestones to which I have committed: * Myoglobin Test and RAMP Reader in FDA Trials March 2001 * Myoglobin Test and RAMP Reader FDA Submission June 2001 * Myoglobin Test and RAMP Reader FDA Clearance September 2001 (expected) * Troponin I and CK-MB Test FDA Submission March 2002 This most recent achievement combined with anticipated near-term FDA clearance is enhancing our ability to solidify marketing and development relationships. In February we signed an agreement to develop and market a test for prostate cancer with Nippon Kayaku Co. Ltd. who specialize in anti-cancer drugs and have annual net sales exceeding US$1 billion. PSA has revolutionized the diagnosis and management of prostate cancer. It is estimated that over US$400 million is currently spent globally on PSA testing. Under the terms of the agreement, they will fund the development of the RAMP PSA test. Nippon Kayaku will then market the RAMP PSA test in Japan while Response Biomedical retains sales and marketing rights for the rest of the world. This is a prime example of a major international company choosing RAMP as the point-of-care system of the future. In a move toward solidifying the Company's financial position, on February 6 we closed a private placement financing for $1.35 million. That 19 of our employees participated in this financing not only underscores their support for Response, but also shows a firm belief in the viability and value of RAMP. Over the past two weeks we have shared our accomplishments and business strategy with a receptive audience of investors in Vancouver, Calgary, Toronto and Montreal and demonstrated, first hand, the RAMP System in action. We are dedicated to realizing our technical, business and financial goals. I look forward to sharing more progress with you in the near future. Again, please feel free to contact Ryan Males, our Manager of Corporate Communications, or myself with any comments or questions you may have. Sincerely, <<...>> Bill Radvak President & CEO Confidentiality Notice. The information contained in this communication is confidential and /or proprietary business or technical data. If you are not the intended recipient you are hereby notified that any dissemination, copying or distribution of this communication, or the taking of action in reliance on the content of this communication, is strictly prohibited. If you have received this communication in error, please immediately notify us by telephone 604.681.4101 or electronically by return message, and delete or destroy all copies of this communication. Ryan Males, Ph.D. Manager, Corporate Communications Response Biomedical Corp. 8855 Northbrook Court Burnaby, BC Canada V5J 5J1 Phone: 604.681.4101 Fax: 604.412.9830 Email: rmales@responsebio.com www.responsebio.com